Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 31-40 of 51

Page
per page
  1. Ki16198
    B1591 Ki16198
    Target: LPA Receptors
    Summary: LPA antagonist
  2. Everolimus (RAD001)
    A8169 Everolimus (RAD001)
     8 Citation
    Target: mTOR
    Summary: MTOR inhibitor
      ≥47.91 mg/mL
  3. Talabostat mesylate
    B3941 Talabostat mesylate
     2 Citation
    Target: DPP-4
    Summary: orally active, specific inhibitor of DPP4
      ≥11.45 mg/mL
  4. TH-302
    A3872 TH-302
    Summary: Hypoxia-activated prodrug,inhibits H460/HT29 cell growth
      ≥22.45 mg/mL
  5. XMD8-92
    A3943 XMD8-92
    Target: ERK
    Summary: BMK1/ERK5 inhibitor
      ≥23.75 mg/mL
  6. Ruxolitinib (INCB018424)
    A3012 Ruxolitinib (INCB018424)
     4 Citation
    Target: JAK
    Summary: JAK inhibitor
      insoluble in H2O; ≥15.32 mg/mL
  7. Trametinib (GSK1120212)
    A3018 Trametinib (GSK1120212)
     7 Citation
    Target: MEK
    Summary: MEK1 and MEK2 inhibitor, potent and selective
      insoluble in H2O; insoluble in EtOH; ≥15.38 mg/mL
  8. RO4929097
    A4005 RO4929097
     1 Citation
    Summary: γ secretase inhibitor
      ≥23.47 mg/mL
  9. AUY922 (NVP-AUY922)
    A4057 AUY922 (NVP-AUY922)
     1 Citation
    Target: HSP90
    Summary: Potent Hsp90 inhibitor
      ≥23.27 mg/mL
  10. Valproic acid sodium salt (Sodium valproate)
    A4099 Valproic acid sodium salt (Sodium valproate)
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC inhibitor
      ≥8.35 mg/mL

Items 31-40 of 51

Page
per page